Correlation Between Vincerx Pharma and Bioatla
Can any of the company-specific risk be diversified away by investing in both Vincerx Pharma and Bioatla at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Vincerx Pharma and Bioatla into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Vincerx Pharma and Bioatla, you can compare the effects of market volatilities on Vincerx Pharma and Bioatla and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Vincerx Pharma with a short position of Bioatla. Check out your portfolio center. Please also check ongoing floating volatility patterns of Vincerx Pharma and Bioatla.
Diversification Opportunities for Vincerx Pharma and Bioatla
0.12 | Correlation Coefficient |
Average diversification
The 3 months correlation between Vincerx and Bioatla is 0.12. Overlapping area represents the amount of risk that can be diversified away by holding Vincerx Pharma and Bioatla in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Bioatla and Vincerx Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Vincerx Pharma are associated (or correlated) with Bioatla. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Bioatla has no effect on the direction of Vincerx Pharma i.e., Vincerx Pharma and Bioatla go up and down completely randomly.
Pair Corralation between Vincerx Pharma and Bioatla
Given the investment horizon of 90 days Vincerx Pharma is expected to under-perform the Bioatla. In addition to that, Vincerx Pharma is 1.17 times more volatile than Bioatla. It trades about -0.25 of its total potential returns per unit of risk. Bioatla is currently generating about -0.01 per unit of volatility. If you would invest 168.00 in Bioatla on September 14, 2024 and sell it today you would lose (24.00) from holding Bioatla or give up 14.29% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Insignificant |
Accuracy | 100.0% |
Values | Daily Returns |
Vincerx Pharma vs. Bioatla
Performance |
Timeline |
Vincerx Pharma |
Bioatla |
Vincerx Pharma and Bioatla Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Vincerx Pharma and Bioatla
The main advantage of trading using opposite Vincerx Pharma and Bioatla positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Vincerx Pharma position performs unexpectedly, Bioatla can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bioatla will offset losses from the drop in Bioatla's long position.Vincerx Pharma vs. Puma Biotechnology | Vincerx Pharma vs. Iovance Biotherapeutics | Vincerx Pharma vs. Day One Biopharmaceuticals | Vincerx Pharma vs. Inozyme Pharma |
Bioatla vs. Pmv Pharmaceuticals | Bioatla vs. C4 Therapeutics | Bioatla vs. Nautilus Biotechnology | Bioatla vs. Century Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Other Complementary Tools
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |